Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 180 versus UROVIST MEGLUMINE DIU CT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 180 versus UROVIST MEGLUMINE DIU CT.
OMNIPAQUE 180 vs UROVIST MEGLUMINE DIU/CT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that radiates X-rays due to high iodine content, attenuating X-ray beams and enhancing vascular/tissue contrast.
Urovist Meglumine DIU/CT is a contrast agent containing meglumine diatrizoate, an ionic monomeric iodinated radiopaque medium. It attenuates X-rays, enhancing vascular and tissue contrast during imaging. The diatrizoate ion increases plasma osmolality, potentially causing vasodilation and hemodynamic effects.
Intravenous: 50-200 mL of 180 mgI/mL (9-36 g iodine) administered as a bolus or infusion, depending on imaging procedure and patient size; typical CT dose: 100-150 mL.
Intravenous administration: 100-200 mL of a 30% solution (containing 30% meglumine diatrizoate) infused over 10-30 minutes for CT imaging. Repeated doses may be given up to a maximum total dose equivalent to 4.0 mL/kg.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe impairment)
Terminal elimination half-life 1–2 hours in patients with normal renal function. Prolonged to >20 hours with severe renal impairment (CrCl <30 mL/min).
Renal: >95% unchanged by glomerular filtration within 24 hours; Biliary/Fecal: <5%
Renal: >95% unchanged within 24 hours by glomerular filtration. Biliary/fecal: <5%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent